| Recruiting | Invasive Candidiasis in Critical Care NCT06456151 | University Hospital Ostrava | — |
| Recruiting | Comparison of Uncomplicated Candidemia Therapy Duration in Children NCT05763251 | Arkansas Children's Hospital Research Institute | N/A |
| Completed | A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus NCT05707832 | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 3 |
| Completed | Evaluate Bioequivalence of Micafungin (50mg/Vial) NCT05496725 | Yung Shin Pharm. Ind. Co., Ltd. | Phase 4 |
| Completed | Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in A NCT04368559 | Mundipharma Research Limited | Phase 3 |
| Unknown | Amphotericin B Cholesteryl Sulfate Complex for Injection(ABCD) in the Treatment of Invasive Candidiasis and In NCT04225195 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 2 |
| Terminated | Comparison of Two Diagnostic Tests in Patients With Suspected Invasive Candidiasis in Internal Medicine Wards NCT03906916 | Fadoi Foundation, Italy | Phase 4 |
| Recruiting | Early Discontinuation of Empirical Antifungal Therapy and Biomarkers NCT03538912 | University Hospital, Lille | N/A |
| Completed | Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractor NCT03059992 | Scynexis, Inc. | Phase 3 |
| Completed | CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidias NCT02734862 | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 2 |
| Completed | NOBICS - NOvel BIomarker In Invasive CandidiasiS/Candida Sepsis NCT02801682 | Medical University of Graz | — |
| Completed | Non-Conventional Microbiological Methods in the Diagnosis of Candidemia NCT07422155 | Institute of Oncology Ljubljana | N/A |
| Completed | BIOPIC: Fungal Biomarkers for Diagnosis and Response to Therapy for Pediatric Candidemia NCT02220790 | Duke University | — |
| Completed | Variability of Fluconazole Concentration in Critically Ill Patients NCT02491151 | University Medical Center Groningen | — |
| Completed | Pharmacokinetics of Micafungin in Patients of Intensive Care Units NCT02164890 | University Hospital, Limoges | Phase 4 |
| Completed | Genetic Susceptibility Factors for Candidemia. NCT02841501 | University Hospital, Lille | — |
| Completed | Pharmacokinetics of Micafungin in Children on Extracorporeal Membrane Oxygenation NCT01666769 | Kevin Watt | Phase 1 |
| Completed | Pharmacokinetics of Micafungin in Critically Ill Patients NCT01716988 | University Medical Center Groningen | — |
| Completed | Invasive Candidiasis in Saudi ICUs NCT01490684 | Hasan Al-Dorzi | — |
| Completed | Empirical Antifungal Treatment in ICUS NCT01773876 | University Hospital, Grenoble | Phase 3 |
| Unknown | Anidulafungin Pharmacokinetics in Intensive Care Unit Patients NCT01438216 | Amsterdam UMC, location VUmc | — |
| Terminated | Pilot Feasibility Study With Patients Who Are at High Risk For Developing Invasive Candidiasis in a Critical C NCT01045798 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Pharmacokinetics of Anidulafungin on Intensive Care Unit (ICU) NCT01047267 | University Medical Center Groningen | — |
| Completed | Candida Spp. in the Lower Respiratory Tract: Harmless Residents or Pathogen? NCT00786903 | Robert Krause, MD | — |
| Terminated | Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins NCT01213823 | Pfizer | — |
| Completed | Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study NCT00689338 | Pfizer | Phase 3 |
| Completed | β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surg NCT00672841 | Duke University | N/A |
| Completed | This Is An Open-Label, Non-Comparative Study Designed To Evaluate A Short Course Of IV Anidulafungin, Followed NCT00548262 | Pfizer | Phase 4 |
| Completed | Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug NCT00608335 | Astellas Pharma Inc | Phase 1 |
| Completed | Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the D NCT00607763 | Astellas Pharma Inc | Phase 1 |
| Completed | Randomized Study of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in the In NCT00520234 | Mycoses Study Group | Phase 4 |
| Completed | CRITIC - Treatment of Candidemia and Invasive Candidiasis NCT00670657 | Gilead Sciences | Phase 4 |
| Completed | A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy NCT00250432 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Micafungin Versus Fluconazole in the Treatment of Invasive Candidiasis and Candidemia NCT00189709 | Astellas Pharma Inc | Phase 3 |